MEDI 7510

Drug Profile

MEDI 7510

Alternative Names: MEDI7510; RSV sF+GLA-SE

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 07 Nov 2016 MedImmune terminates phase II trial in Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in USA, Canada, Chile, Estonia, Latvia, Lithuania and South Africa.(NCT02508194)
  • 28 Feb 2016 MedImmune completes a phase Ib trial for Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in USA (NCT02289820)
  • 06 Nov 2015 Phase-II clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in Latvia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top